Angiotensin II (Ang II) receptor blockers are the newest class of antihypertensive drugs to be developed. No large-scale clinical trials have been performed to evaluate their efficacy alone, or in combination with other drugs. A large-scale, eight week, open-label, non-placebocontrolled, single-arm trial evaluated the efficacy, tolerability and dose-response of candesartan cilexetil, 16-32 mg once-daily, either as monotherapy or as part of combination therapy, in a diverse hypertensive population in actual practice settings. 6465 patients with high blood pressure, of whom 52% were female and 16% African American, with a mean age of 58 years, were included. 5446 patients had essential hypertension and 1014 patients had isolated systolic hypertension. In order to be included in this study, patients had either untreated or uncontrolled hypertension (systolic blood pressure (SBP) 140-179 mmHg and/or diastolic blood pressure (DBP) 90-109 mmHg inclusive at baseline), despite a variety of other antihypertensive drugs. Of the 5156 patients with essential hypertension and at least one post baseline efficacy measurement, the mean pretreatment blood pressure (BP) was 156/97 mmHg. Candesartan cilexetil monotherapy reduced mean SBP/DBP by 18.0/12.2 mmHg. Similarly, in the 964 patients with isolated systolic hypertension and at least one post baseline efficacy measurement, candesartan cilexetil monotherapy reduced SBP/DBP from 158/81 by 16.5/4.5 mmHg. Candesartan cilexetil was similarly effective when employed as add-on therapy. When added to baseline antihypertensive medication in 51% of the patients with essential hypertension not achieving BP control, additional reduction in BP was achieved regardless of the background therapy, including diuretics (17.8/11.7 mmHg) calcium antagonists (16.6/11.2 mmHg), betablockers (16.5/10.4 mmHg), angiotensin-converting enzyme inhibitors (ACE-I) (15.3/10.0 mmHg), and alpha blockers (16.4/10.4 mmHg). Likewise, when candesartan cilexetil was used as add-on therapy in patients with isolated systolic hypertension, there was a consistent further reduction of mean SBP/DBP, regardless of the background therapy. Moreover, these monotherapeutic or add-on efficacy benefits were seen regardless of age (<65 or >65 years), gender, or race. Despite the open-label design of the study which enhances efficacy owing to the placebo effect, the Ang II receptor blocker, candesartan cilexetil either alone, or as an add-on therapy, is highly effective for assisting in the control of systolic and diastolic hypertension.
Introduction
A growing conundrum in clinical practice is how to achieve the lower levels of blood pressure (BP) which are now indicated as being important in delaying progression of cardiovascular disease. Consensus recommendations from JNC VI have called for more intensive BP control levels (<130/85 mmHg), if there is any evidence of cardiovascular disease, kidney disease or diabetes. 1 However, this is not customarily achieved in clinical practice. 2 Frequently, hypertensives are treated late in the course of their disease when it has been manifest for many years. Consequent structural changes within the arterial wall associated with higher levels of pressure result in the disease process being more difficult to treat. Thus, when many patients come to the physician's office with systolic blood pressure (SBP) in the 150-160 mmHg range, they are likely to require two or possibly three medications in order to achieve the goal BP of 130-140 mmHg systolic. Thus, not only are well-tolerated medications needed, but also medications that work well with one another and can assist in achieving goal BP.
With the introduction of the angiotensin II (Ang II) receptor blockers a few years ago, another therapeutic class targeting the renin-angiotensinaldosterone system (RAAS) was available for clinical practice. However, large-scale clinical practice trials had not yet been conducted to provide information concerning the use of these drugs, either alone or in combination with other drugs, in various demographic groups. It is important to conduct these types of clinical experience trials, as they may provide results that may be somewhat different from smaller controlled trials in research centres that provide more intensive follow-up and supervision of patients. In addition, the doses employed in practice may not always reflect the doses used in controlled studies. Open-label clinical trials provide the physician with the opportunity to use agents in their accustomed doses and evaluate efficacy in the setting of ad-lib diet and without rigid control of follow-up visits.
Candesartan cilexetil is a highly-selective, insurmountable AT 1 -receptor Ang II blocker (ARB) devoid of agonist activity. 3 Controlled clinical studies have demonstrated a dose-related antihypertensive effect with once-daily dosing and a high trough-to-peak ratio. [4] [5] [6] Like other angiotensin receptor blockers, it has demonstrated an excellent safety and tolerability profile which is similar to placebo.
The ACTION trial was designed as a large-scale, open-label, clinical experience trial, in which approximately 600 physicians had an opportunity to enroll about 10 patients each in order to evaluate the efficacy of candesartan cilexetil, either alone or in combination with other agents, in patients with essential or isolated systolic hypertension, in order to facilitate control of BP.
Material and methods

Study design
The study design incorporated an open-label, nonplacebo-controlled, multicentre, single-arm evaluation of the use of candesartan cilexetil in 6465 patients with essential hypertension or isolated systolic hypertension at 655 investigative sites ( Figure 1 ).
Study subjects
Eligibility was based on patients being either untreated or having uncontrolled hypertension on medication, with a sitting SBP in the range of 140-179 mmHg and/or diastolic blood pressure (DBP) of 90-109 mmHg, inclusive, at baseline.
Medication dosing
Patients were given candesartan cilexetil, 16 mg once-daily, either alone or in addition to concomitant antihypertensive medications. Background therapy with one or more drugs was permitted, with the exception of the concomitant use of another ARB. Patients returned for study visits after two, four, and eight weeks of treatment. If BP remained uncontrolled (either DBP >90 mmHg or SBP >140 mmHg at either week two or four), candesartan cilexetil was increased to 32 mg oncedaily. Decreases in study drug dose or changes in background therapy were not permitted.
Efficacy endpoint
For patients with essential hypertension, the primary efficacy endpoint was the change in trough (24±2 hours) sitting DBP, from baseline visit to the end of week eight. Similarly, for patients with isolated systolic hypertension, the primary efficacy endpoint was the change in trough sitting SBP, from baseline to the end of week eight. Controlled BP was defined as DBP <90 mmHg in the essential hypertension group and SBP <140 mmHg in the isolated systolic hypertension group.
Safety
Investigators reported treatment-emergent adverse events that began or worsened during the course of the study. These were noted to be either related or unrelated to the use of the study drug candesartan cilexetil.
Statistical analysis
Statistical analysis using the paired t-test was performed on the mean changes in BP from baseline to week eight, to evaluate the effects of either monotherapy or add-on therapy with candesartan S218 PAPER Figure 1 Study design: Candesartan cilexetil dosage was up-titrated from 16 mg once-daily to 32 mg once-daily in patients with uncontrolled hypertension (diastolic blood pressure >90 mmHg). cilexetil, 16-32 mg once-daily. A p-value of <0.05 was assumed to be statistically significant. Descriptive statistics were used to evaluate possible differences in outcome due to age, gender, race and class of background antihypertensive agents. The numbers of patients in the subgroups may not add up to the total owing to occasional missing data and may differ slightly, owing to the use of the intent-to-treat approach to analyse the data. The efficacy population included all patients who had baseline measurements and at least one observation while on open-label treatment. Table 1 depicts the demographic background of the overall study population. Forty-nine percent of the patients with essential hypertension received candesartan cilexetil monotherapy, compared with only 34% of the patients with isolated systolic hypertension. Note that the patients were middleaged with a mean age of 56 years, modestly overweight and had diagnosed hypertension for a number of years. Sixteen percent of the patients were African Americans. On the other hand, patients with isolated systolic hypertension were less heavy and older, with a larger proportion of females.
Results
Study population
Dose response
Candesartan cilexetil was given as monotherapy in 49% of the hypertensive patients. After eight weeks of therapy, nearly half (46%) of all essential hypertensive patients were maintained on 16 mg daily while the remainder were titrated to 32 mg daily. As demonstrated in Figure 2 , after eight weeks of therapy with either 16 or 32 mg of candesartan once-daily, SBP/DBP had been reduced from 156/97 to 138/85, a change of 18.0/12.2 mmHg from baseline. As seen in this figure, the BP-lowering effects were similar, regardless of gender, race, age or pretreatment DBP (>100 or <100). There were somewhat diminished effects in African Americans, compared with Caucasians.
For the 54% of patients who were uncontrolled on candesartan cilexetil 16 mg and who were thus titrated to 32 mg, mean BP was further reduced by 8/5 mmHg at the end of eight weeks of therapy. As depicted in Figure 3 , the incremental benefit of increasing the dose of candesartan cilexetil was consistent across gender, race, age and pretreatment DBP. Thus, candesartan cilexetil 16-32 mg once-daily achieved an overall control rate (DBP <90 mmHg) in clinical practice of 71%. As seen in Figure 4 , this response rate was similar across all demographic groups, although somewhat less in African Americans and in patients with Stage 2 hypertension.
Efficacy either alone or as add-on therapy in patients with essential hypertension
More than half the patients (51%) received candesartan cilexetil as add-on therapy (n=2642). Figure 5 illustrates the additional antihypertensive effects of candesartan cilexetil when added to other background therapies. Note the additional BP reduction regardless of whether a diuretic, calcium antagonist, beta-blocker, ACE-I, or alpha blocker is employed. All reductions seen here are statistically significant. Moreover, these incremental benefits with the add-on of candesartan cilexetil 16-32 mg once-daily were observed regardless of gender, age, or race. 7
Antihypertensive effects of candesartan cilexetil either alone or as add-on therapy in patients with isolated systolic hypertension
Candesartan cilexetil, 16-32 mg once-daily, either alone or as an add-on therapy, reduced SBP/DBP from 158/81 mmHg to 142/76 mmHg, a mean reduction of -16.5/-4.5 mmHg. 8 When used as monotherapy, candesartan cilexetil reduced Figure  6 , the BP-lowering effects of candesartan cilexetil were noticeable in all demographic groups, though perhaps a little less so in African Americans. Titration of candesartan cilexetil from 16-32 mg daily, either alone or as an add-on therapy, facilitated further BP reduction as shown in Figure 7 , and resulted in an overall control rate (SBP <130 mmHg) of 49%.
Discussion
The treatment of essential hypertension and isolated systolic hypertension remains an important clinical conundrum. Cardiovascular endpoint trials illustrate the importance of achieving lower levels of systolic 9-11 and diastolic BP. 12 Yet, clinical experience has demonstrated that achieving these levels of BP requires multiple medications and more intensive therapy. Moreover, there is additional evidence that specifically targeting the RAAS as part of a multidrug strategy to lower BP may have additional benefit, particularly in patients with heart disease, kidney disease, and diabetes.
With the introduction of ARB five years ago, there was much discussion as to where they would fit in clinical practice. Would they be therapies that were so effective that they would stand alone? How would they differ from ACE-I? Could they be used with ACE-I? Many of these questions can now be answered in this large clinical experience trial. For the first time, there is evidence that these drugs are as effective as other commonlyused drugs when used alone. This supports the data from numerous controlled clinical trials illustrating comparable efficacy of ARBs with calcium antagonists, ACE-I, beta-blockers, and diuretics.
Moreover, the results of this large US trial, provides very similar efficacy results to a similar, smaller, clinical experience trial, conducted with 4531 patients in Europe. 13 This clinical experience trial also provides some answers with regard to the impact of demographics on the response to an ARB. As illustrated herein, the efficacy of the ARB was comparable, regardless of age and gender, in the treatment of high BP. There was some modest diminution of BP reduction in African Americans. However, it is important to note that antihypertensive benefit was present in this population and could be incrementally improved with titration or use of candesartan cilexetil with other drugs.
This clinical experience trial also importantly demonstrated the efficacy of the ARB in reducing SBP. Moreover, the reduction in SBP was not associated with a sizable reduction in DBP. This is important, as there is some concern that excessive reduction in DBP could result in increased risk of myocardial ischaemia. These results should therefore encourage the use of these drugs, either alone or in combination with other drugs, in the treatment of isolated systolic hypertension.
Whether to use an ARB alone or in combination with other drugs has also been carefully examined in this trial. It is interesting to note that candesartan cilexetil was equally effective in reducing BP as monotherapy or when added to other commonly-used drugs, including ACE-I. This latter observation is somewhat controversial. Although most studies 14, 15 show additional BP reduction when adding an ARB to an ACE-I, full dose titration has not been utilised to see whether an ARB added to high dose ACE-I would result in incremental BP reduction. Clinical studies, although showing an incremental benefit when adding an ACE-I to an ARB, or vice versa, have not shown these benefits to be truly additive. In this study, the incremental efficacy of adding an ARB to an ACE-I was every bit as large as adding it to a calcium antagonist or a diuretic. Thus, in clinical experience, with the doses of antihypertensive drugs commonly employed by physicians, an ARB can be used routinely to improve antihypertensive efficacy.
This large study also provided some insight into whether or not increasing the dose of candesartan cilexetil would improve efficacy. Both for the overall group and for patients with isolated systolic hypertension, increasing the dose from 16-32 mg, either alone or in combination with other drugs, resulted in statistically significant improvements in BP reduction. This was true regardless of age, gender, race, or pretreatment BP. This is an important observation in a clinical experience study, since increasing the dose of the drug was not associated with an increase in adverse events. These data support the results of controlled clinical studies which demonstrate a doseresponse with candesartan cilexetil. 16 In this study, the tolerability of the ARB was well demonstrated. Overall, only 6% of the essential hypertensive patients withdrew due to side effects. Most important adverse events were Trough values were determined 24±2 hours after the last dose of candesartan cilexetil and expressed as mean ± standard error. *p<.0.05, changes in blood pressure from last measurement on 16 mg once-daily to last measurement on 32 mg once-daily. Male (n=175); female (n=300); black (n=52); non-black (n=423); age <65 years (n=146); age > 65 years (n=329). SEM = standard error of mean. dizziness, headaches, and orthostatic hypertension. Hypotension was infrequent (0.6%). This large, clinical experience trial provides important new observations concerning the use of the ARB, candesartan cilexetil, in the treatment of essential and isolated systolic hypertension, either alone or as add-on therapy. It supports the use of candesartan cilexetil on a broad scale in clinical practice because of its simplicity of dosing, excellent tolerability and, most importantly, its efficacy. While the study was conducted in an openlabel design, consistent with clinical practice, the efficacy is substantial even if one subtracts out a placebo effect which could be as much as 5 mmHg systolic. 17 It is important to study new therapies, in both randomised placebo-controlled trials and clinical experience trials, to get a full understanding of overall efficacy.
